Women physician leaders have made significant contributions in various fields, such as business leaders as CEOs and board members, public health through national and international advocacy efforts, and the non-profit sector.

"To Lead or Not To Lead" - that is the question.

Lancet Rheumatology has published a retrospective analysis showing patients receiving immune checkpoint inhibitors (ICI) for cancer have the same outcomes (mortality and severe immune-related adverse events (irAEs)) even when they have pre-existing rheumatoid arthritis (RA).

Although almost half of our specialist rheumatology physician workforce is now women, gender inequity in career progression within academic rheumatology is a persistent problem. A recent analysis of the US rheumatology workforce showed that although women were well represented in rheumatology program director and division director leadership roles, women academics were less likely to be full or associate professors, had fewer publications, and received fewer NIH grants.